Basics of Immunotherapy Potential Therapeutic Targets.

Slides:



Advertisements
Similar presentations
Advancing Care Forward in Squamous Cell Carcinoma of the Head and Neck
Advertisements

Bladder Cancer: A New Era in Treatment
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.
Evolving Paradigms in Recurrent/Metastatic SCCHN
Nat. Rev. Clin. Oncol. doi: /nrclinonc
A New Path Forward: Immune Checkpoint Inhibitors in Bladder Cancer
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States and data.
Treatment Algorithms in Melanoma: Past, Present, and Future
Program Goals. Clinical Considerations in the Use of Checkpoint Inhibitors for Gastrointestinal Cancers.
T-Cell Exhaustion: Can We Overcome It in Cancer?
Advanced NSCLC Without Actionable Mutations
State of the Art in HCC: Immune Checkpoint Modulation
New Patient Journeys in Non-small cell lung cancer
Essential Concepts in Harnessing the Immune System in Head and Neck Cancer.
Spotlight on Immuno-Oncology in Melanoma
REFLECT: First-Line Lenvatinib vs Sorafenib in HCC Study Design
Metastatic Renal Cell Carcinoma
Learning Objectives. A Multidisciplinary Approach in Advanced NSCLC in the Era of Immuno-Oncology.
Updates in Lung Cancer: Insights From Vienna
Optimizing the Treatment of Recurrent/Metastatic SCCHN
Activity Goals. Activity Goals Discussion Topics.
Program Goals Introduction Case 1: A 44-Year-Old Woman.
Management of Glioblastoma
The Evolving Role of Immunotherapy in NSCLC
Immunotherapy in Pancreatic Cancer: Thinking Outside the Box
Locally Advanced NSCLC Implementing Innovation
Treating mRCC After Initial Antiangiogenic Therapy:
Advanced Lung Cancers: What's on the Horizon?
The Emerging Role of Immunotherapy in Hodgkin Lymphoma
Next-Gen Psoriasis Therapies:
Essential Concepts in the Use of Immunotherapies in Bladder Cancer
Nat. Rev. Clin. Oncol. doi: /nrclinonc
Emerging Frontline Treatments for Patients With Hodgkin Lymphoma
Advancing Care in Genitourinary Cancer: Perspectives From Chicago
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data.
Evolving Concepts in the Management of Head and Neck Cancers
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.
Immune Checkpoint Inhibitors in Lung Cancer
Locally Advanced Lung Cancer
Advances in Gastrointestinal Cancers
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.
Progress of the NSCLC Revolution
Moving the Goal Post: Multidisciplinary Management of Advanced NSCLC
Patient-Centered Management in Advanced Non-Small Cell Lung Cancer
Challenges and Opportunities
Preparing for Checkpoint Inhibitors in Breast Cancer
This program will include a discussion of off-label treatment and investigational agents not approved by the Food and Drug Administration for use in the.
Novel Concepts in the Management of RCC
Debates and Dilemmas, Part 1
From Adjuvant to Metastatic in Melanoma
Immune Checkpoint Inhibitors in EGFR-Mutated NSCLC
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data.
Activity Goals. Clinical Considerations in the Use of Immune Checkpoint Inhibitors in Advanced NSCLC.
Checkpoint Inhibitors in First-Line Advanced NSCLC
Clinical Considerations in the Use of Checkpoint Inhibitors Breast Cancer.
Taking a Closer Look at Recurrent/Metastatic SCCHN
A Pharmacist's Guide to Safety and Use of Immune Checkpoint Inhibitors
Going Beyond EXTREME in Head and Neck Cancer
Moving Care Forward in Advanced Gastric Cancer
Finding the Right Sequence in Patients With EGFR-Mutated NSCLC
New Options for the Treatment of Hepatocellular Carcinoma
MSI.
Current Status of Biomarkers for Immune Checkpoint Inhibitors
Immune Checkpoint Inhibitors in Lung Cancer
Combining Immunotherapy and Chemotherapy in NSCLC
The Nurse View.
The Nurse View: Practice Pearls in the Use of Immune Checkpoint Inhibitors in Advanced NSCLC.
Recent Developments in the Treatment of Advanced and Metastatic RCC
Updates in Best Practices in Non-Small Cell Lung Cancer
Presentation transcript:

Basics of Immunotherapy

Potential Therapeutic Targets

Common Checkpoint Molecules in Immunotherapy

Nivolumab

Pembrolizumab

Toxicity With Checkpoint Inhibitors

Key Points Regarding Toxicity

Considerations for Toxicity Management

Completed Studies With First-Line Checkpoint Inhibitors

First-Line Anti-PD-L1: Durvalumab

CheckMate 012 Efficacy Results

CheckMate 012 Safety Results

CheckMate 568

KEYNOTE-021 Design

KEYNOTE-021 Efficacy Results

KEYNOTE-021 Safety Results

Other Treatment Considerations

POPLAR Study Outcomes

Additional Combination Studies

PD-L1 Testing

IFNγ as a Biomarker in Durvalumab in NSCLC

Additional Second-Line Checkpoint Inhibitor Combination Studies

Concluding Remarks

Abbreviations

Abbreviations